Perceptive Advisors LLC Grows Holdings in Alto Neuroscience, Inc. $ANRO

Perceptive Advisors LLC boosted its position in Alto Neuroscience, Inc. (NYSE:ANRO) by 12.6% in the first quarter, HoldingsChannel reports. The firm owned 2,009,893 shares of the company’s stock after buying an additional 225,500 shares during the quarter. Alto Neuroscience accounts for about 0.9% of Perceptive Advisors LLC’s holdings, making the stock its 27th largest holding. Perceptive Advisors LLC owned approximately 0.06% of Alto Neuroscience worth $45,182,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Commodore Capital LP bought a new position in shares of Alto Neuroscience during the 4th quarter worth approximately $32,453,000. Vestal Point Capital LP grew its holdings in shares of Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after acquiring an additional 1,535,000 shares in the last quarter. Spruce Street Capital LP grew its holdings in shares of Alto Neuroscience by 494.7% in the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after acquiring an additional 1,102,366 shares in the last quarter. Vivo Capital LLC purchased a new stake in shares of Alto Neuroscience during the fourth quarter valued at approximately $18,433,000. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Alto Neuroscience during the first quarter valued at approximately $11,240,000.

Alto Neuroscience Trading Down 5.4%

Shares of ANRO stock opened at $27.09 on Friday. The company has a 50 day moving average of $24.11 and a 200-day moving average of $21.90. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience, Inc. has a 12-month low of $3.00 and a 12-month high of $28.85. The firm has a market cap of $950.76 million, a P/E ratio of -11.20 and a beta of 1.04.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Sell-side analysts anticipate that Alto Neuroscience, Inc. will post -3.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ANRO. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research report on Wednesday, June 17th. Wolfe Research began coverage on Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Robert W. Baird decreased their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Zacks Research cut Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Finally, Bank of America assumed coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.